PROM1 and neoplasm: As shown in Fig. 1f, g, i, triple treatment induced more CD122+ tumor-specific CD8+ T cells than RT/anti-PD1 in tumor-draining lymph nodes (TDLNs), blood, and spleen in both the B16-CD133 and the C51 models.